BC Week In Review | Feb 15, 2019
Clinical News

Cellular BioMedicine to test stem cell therapy in Chinese Phase II for knee osteoarthritis

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) said China's National Medical Products Administration (NMPA) approved an IND for a Phase II trial of AlloJoin to treat knee osteoarthritis. The product is an allogeneic adipose-derived mesenchymal progenitor cell...
BC Week In Review | Apr 14, 2017
Company News

Cellular Biomedicine, GE deal

Cellular Biomedicine and the GE Healthcare Life Science China unit of General Electric Co. partnered to jointly develop automated systems for manufacturing chimeric antigen receptor T cell and stem cell therapies. The partners said the...
BC Extra | Apr 11, 2017
Company News

Cellular Biomedicine, GE in China cell manufacturing deal

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) said it partnered with the GE Healthcare Life Science China unit of General Electric Co. (NYSE:GE) to jointly develop automated systems for manufacturing chimeric antigen receptor T cell and stem...
BC Week In Review | Mar 10, 2017
Company News

CIRM funding news

CIRM awarded $32.6 million in grants to fund clinical trials and R&D. Caladrius will receive up to $12.2 million for its ongoing Phase II trial of autologous T regulatory cells ( CLBS03 ) to treat recent-onset Type...
Items per page:
1 - 4 of 4